Please assess the completion status of the following clinical trial:

Trial Title: Assessment of Fluticasone Propionate on Ocular Allergy Symptoms

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Participants with good general health (in the opinion of the investigator) with no clinically significant and relevant abnormalities of medical history~2. Participants with diagnosis of seasonal allergic rhinitis~   1. A clinical history (written or verbal confirmation) of allergic rhinitis with the seasonal onset and offset of nasal and ocular allergy symptoms during each of the last 2 mountain cedar pollen allergy seasons.~  2. A positive skin test reaction to (at least) the relevant allergen, mountain cedar pollen, as determined by the skin pricks method performed within 12 months of Visit 1).~3. Participants with allergic rhinitis symptom of at least moderate severity for randomization:~   1. An iTOSS of ≥ 4 and an iNCSS of ≥2 on the morning of randomization (Visit 3/Baseline).~  2. An averaged (rTOSS) of ≥ 4, and an averaged rNCSS of ≥2 for three of the five days during the placebo lead in~4. Participant residing within a geographical environment where exposure to mountain cedar pollen is significant during the entire study period.~5. Participant demonstrates understanding of the study and willingness to participate as evidenced by voluntary written informed consent/assent and has received a signed and dated copy of the informed consent/assent form. Children, ages 12 to 17 will be required to sign an assent form as part of the informed consent process.~Exclusion Criteria:~1. Participants with known or suspected intolerance or hypersensitivity to the study materials (or closely related compounds) or any of their stated ingredients.~2. Participants with nasal disorders like:~   1. injury or surgery to their nose that the investigator believes would interfere with participation in the study.~  2. previously diagnosed with a severe physical obstruction of the nose (e.g., deviated septum) that could affect the deposition of double-blind intranasal study drug.~  3. Rhinitis medicamentosa~3. Participants who have historical or current evidence of clinically significant uncontrolled disease like asthma, cardiac arrhythmias, hypertension, diabetes mellitus, ocular herpes, glaucoma, hepatic or renal disease, malignancy etc.~4. Presence of or symptoms of an active bacterial or viral infection.~5. Participants who have conjunctivitis caused by an infectious agent.~6. Participants with current, single eye or bilateral cataracts or participants who had cataract surgery within/less than 3 months

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Fluticasone propionate nasal spray (Type: EXPERIMENTAL): Fluticasone propionate nasal spray with strength per dose of 50 mcg/spray. Two sprays of study treatment per nostril to be administered in morning.
- Placebo nasal spray (Type: PLACEBO_COMPARATOR): Two sprays of placebo per nostril to be administered in morning.

Based on this trial design, predict the completion outcome and termination type (if applicable).